Cryosurgery Appears Effective as Primary Treatment for High-Risk
Prostate Cancer Patients

IRVINE, CA -- April 18, 2005 -- Endocare, Inc. (OTC: ENDO), an
innovative medical device company focused on the development of
minimally invasive technologies for tissue and tumor ablation along with
vacuum technologies for erectile dysfunction, today announced that data
from a study performed at New York's Columbia Presbyterian Medical
Center, and published in the scientific journal CANCER, showed
additional promising results for men who choose cryoablation as the
primary means of treating prostate cancer, even when those patients were
considered to be in a high-risk profile.

The 65-patient study, in which the Endocare Cryocare(R) system was used
principally, examined the results of men who elected to have prostate
cryosurgery as their primary therapy between January 1998 and April
2002. All of the men in the study exhibited symptoms deemed high-risk,
including prostate-specific antigen (PSA) levels greater than or equal
to 10 ng/mL and/or a Gleason sum score greater than or equal to 8.
Following the procedure, patients were monitored via physical
examinations and PSA screening every three months and with radiologic
imaging in some cases. After a median follow-up period of 35 months (the
range was 4-77 months), the PSA biochemical disease-free survival rate
was 83 percent of patients according to the American Society for
Therapeutic Radiology and Oncology (ASTRO) criteria. The overall
survival rate at the time of publication was 100 percent.

"The progression of data supporting the cryosurgery option as a primary
means of treating prostate cancer, even in a high-risk patient
population or as a secondary or 'salvage' treatment for men who have
failed radiation therapy, continues to accelerate as use of the
procedure increases in the urology community," said Dr. Aaron Katz,
assistant professor of urology at Columbia Presbyterian Center of New
York-Presbyterian Hospital and a principal author of the study.
"Cryosurgery has again been shown to result in long-term cure rates and
has very few complications."

Endocare Chairman and CEO Craig T. Davenport said, "As the technology
and precision of our device have progressed, physicians have become much
more confident in its use in treating a greater proportion of prostate
cancer patients -- even those with more serious conditions or who have
attempted other forms of treatment. In addition to the recently
announced 10-year survival data and numerous studies in the area of
interventional radiology, this study is one more milestone on the road
to broader acceptance and use of our technology, and we appreciate the
efforts of the clinicians and patients who continue to push forward with
valuable research."

knowledge is power - growing old is mandatory - growing wise is optional    
"Many more men die with prostate cancer than of it. Growing old is
invariably fatal. Prostate cancer is only sometimes so."
http://community.webtv.net/PALMER_ENT/doc